Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Clinical trial NCT03552029 · TERMINATED
Trial details
- NCT number
- NCT03552029
- Sponsor
- Daiichi Sankyo
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-12
- Primary completion
- 2021-04-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.